Medicamen Biotech Limited (MEDICAMEQ) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MEDICAMEQ Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Medicamen

Biotech Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MEDICAMEQ Stock 12 Month Forecast

Average Price Target

₹396.00

▲(15.18% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Medicamen Biotech Limited in the last 3 months. The average price target is ₹396.00 with a high forecast of ₹396.00 and a low forecast of ₹396.00. The average price target represents a 15.18% change from the last price of ₹343.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"383":"₹383","586":"₹586","433.75":"₹433.8","484.5":"₹484.5","535.25":"₹535.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":396,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹396.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":396,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹396.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":396,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹396.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[383,433.75,484.5,535.25,586],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,384.55,385.4307692307692,386.3115384615385,387.1923076923077,388.07307692307694,388.95384615384614,389.8346153846154,390.7153846153846,391.59615384615387,392.4769230769231,393.35769230769233,394.23846153846154,395.1192307692308,{"y":396,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,384.55,385.4307692307692,386.3115384615385,387.1923076923077,388.07307692307694,388.95384615384614,389.8346153846154,390.7153846153846,391.59615384615387,392.4769230769231,393.35769230769233,394.23846153846154,395.1192307692308,{"y":396,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,384.55,385.4307692307692,386.3115384615385,387.1923076923077,388.07307692307694,388.95384615384614,389.8346153846154,390.7153846153846,391.59615384615387,392.4769230769231,393.35769230769233,394.23846153846154,395.1192307692308,{"y":396,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":403.87,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":585,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":536.2,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":449.4,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":506.7,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":460.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":508.7,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":494.55,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":426.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":417.5,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":414.35,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":414.35,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":384.55,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹396.00

Average Price Target₹396.00

Lowest Price Target₹396.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bryce Generon

TR | OpenAI - 4o

₹409→₹396

Hold

15.18%

Upside

Reiterated

08/01/25

AI Generated ArticleAI Generated Article

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bryce Generon

TR | OpenAI - 4o

₹409→₹396

Hold

15.18%

Upside

Reiterated

08/01/25

AI Generated ArticleAI Generated Article

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MEDICAMEQ Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MEDICAMEQ has received 0 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. MEDICAMEQ average Analyst price target in the past 3 months is 396.00.

Each month's total comprises the sum of three months' worth of ratings.

MEDICAMEQ Financial Forecast

MEDICAMEQ Earnings Forecast

The previous quarter’s earnings for MEDICAMEQ were ₹1.59.

MEDICAMEQ Sales Forecast

The previous quarter’s earnings for MEDICAMEQ were ₹430.45M.

MEDICAMEQ Stock Forecast FAQ

What is IN:MEDICAMEQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Medicamen Biotech Limited’s 12-month average price target is 396.00.

What is IN:MEDICAMEQ’s upside potential, based on the analysts’ average price target?

Medicamen Biotech Limited has 15.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Medicamen Biotech Limited a Buy, Sell or Hold?

Medicamen Biotech Limited has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Medicamen Biotech Limited’s share price target?

The average share price target for Medicamen Biotech Limited is 396.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹396.00 ,and the lowest forecast is ₹396.00. The average share price target represents 15.18% Increase from the current price of ₹343.8.

What do analysts say about Medicamen Biotech Limited?

Medicamen Biotech Limited’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Medicamen Biotech Limited?

To buy shares of IN:MEDICAMEQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Medicamen Biotech Limited (MEDICAMEQ) Stock Forecast & Price Target

MEDICAMEQ Analyst Ratings

MEDICAMEQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

MEDICAMEQ Analyst Recommendation Trends

MEDICAMEQ Financial Forecast

MEDICAMEQ Earnings Forecast

MEDICAMEQ Sales Forecast

MEDICAMEQ Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts